Surgery Partners Inc (SGRY) Shares Plummet to $19.12 Amid 66.59% Upside Potential

Surgery Partners Inc (SGRY) shares fell 3.60% to $19.12 on Jun 20, with trading volume at 1,720,607 shares, 135.6% above the average daily volume. The stock is 43.72% below its 52-week high and 1.32% above its 52-week low. The average target price from 12 analysts is $31.85, with an upside of 66.59% from the current price. The estimated GF Value in one year is $34.15, indicating an upside of 78.61% from the current price.

Surgery Partners Inc (SGRY) saw its shares fall by 3.60% to $19.12 on June 20, 2025, with trading volume surging to 1,720,607 shares, a 135.6% increase from the average daily volume. The stock is currently trading at 43.72% below its 52-week high of $33.97 and 1.32% above its 52-week low of $19.50. Analysts have set an average target price of $31.85, indicating a potential upside of 66.59% from the current price. The estimated GF Value in one year is $34.15, suggesting an upside of 78.61% from the current price [1].

The decline in SGRY's share price is largely attributed to the conclusion of buyout discussions with Bain Capital. Bain Capital proposed to acquire SGRY at $25.75 per share in January, aiming to purchase the remaining shares it didn't own. However, the company decided to remain independent, citing strong Q1 performance, favorable surgical trends, and a positive regulatory outlook as reasons for staying independent [2].

Despite concerns about potential Medicaid cuts, SGRY downplayed these worries, stating that less than 5% of its revenue comes from Medicaid and exchange-based programs. The company expressed confidence in its future prospects and reaffirmed its FY25 guidance, projecting revenues between $3.30 billion and $3.45 billion, and Adjusted EBITDA between $555 million and $565 million [2].

The stock's recent performance has been volatile, with a 20.05% decline over the past year despite posting robust revenue growth of ~14%. The stock's RSI indicates oversold territory, potentially signaling a technical bottom for this $2.49 billion market cap healthcare services provider [3].

Investors should note that SGRY's beta value is currently sitting at 1.94, indicating higher volatility compared to the broader market. Analysts have defined $31-$64 as the low and high price targets, arriving at a consensus price target of $38 for the trailing 12-month period [3].

The company plans to host an Investor Day in the second half of 2025 to discuss its strategy and outlook, providing further insights into its future prospects [4].

References:
[1] https://www.gurufocus.com/news/2932347/surgery-partners-ends-buyout-talks-with-bain-capital-shares-slide
[2] https://www.investing.com/news/company-news/surgery-partners-stock-hits-52week-low-at-1949-usd-93CH-4104065
[3] https://stocksregister.com/2025/06/17/is-surgery-partners-incs-nasdaqsgry-stock-on-the-decline/
[4] https://www.stocktitan.net/news/SGRY/